Blockade of these mutations with small molecule inhibitors such as sunitinib via the VEGFR cell signaling pathway have led to improved quality of life, tumor size reduction, and control of PC-induced clinical signs such as hypertension [17]. The gene discussed is KDR; the disease is Hypertension.